510(k) device
RTVue XR OCT Avanti with AngioVue Software
Optovue, Inc. · Ophthalmoscope, Ac-Powered (HLI, Class II) · First FDA decision Apr 3, 2012, newest Feb 11, 2016GlaucomaMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
3
Naming "RTVue XR OCT"
MAUDE reports
0
Brand "RTVue XR OCT", since 2015
PubMed studies
8
Mentioning "RTVue XR OCT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing RTVue XR OCT Avanti with AngioVue Software
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K153080 · Decided Feb 11, 2016 · 111 days after receipt
Device type: Ophthalmoscope, Ac-Powered (HLI) · Ophthalmology
- RTVUE XR OCT510(k)
K120238 · Decided Apr 3, 2012 · 68 days after receipt
Device type: Ophthalmoscope, Ac-Powered (HLI) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "RTVue XR OCT", any status and sponsor, newest update first.
- The Potential of Optical Coherence Tomography Angiography (OCTA) to Detect Early Cognitive Dysfunction in Diabetic PatientsActive, not recruiting
Dr. Sefic Eye Polylcinic and Optical StudioAcademic, hospital or other
NCT07135440 · 210 participants (planned) · Start Nov 1, 2024 · Primary completion Oct 30, 2025
Device: OCT angiography RTVue XR Avanti; Optovue, Inc, Fremont, California, USA · For: Type 2 Diabetes Mellitus Diabetic Retinopathy Cognitive Dysfunction
Sites: Sarajevo, Bosnia and Herzegovina
- Agreement and Precision Study of the Nidek MirantePivotal-lookingCompleted
Nidek Co. LTD.Not on our public-company list
NCT04318132 · 170 participants · Start Jan 25, 2020 · Primary completion Dec 30, 2021
Device: Nidek Mirante; Optovue RTVue XR Avanti and 1 more · For: Glaucoma; Retinal Disease; Corneal Disease
Sites: Andover, Massachusetts
- Comparative Study of the Cornea/Anterior Segment OCT CASIA2 and the RTVue XR OCT Avanti With AngioVue SoftwarePivotal-lookingCompleted
Tomey CorporationNot on our public-company list
NCT04486976 · 134 participants · Start Jun 27, 2020 · Primary completion Mar 5, 2021
Device: Cornea/Anterior Segment OCT CASIA2; Optovue RTVue XR Avanti · For: Glaucoma; Cataract
Sites: Andover, Massachusetts
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "RTVue XR OCT", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HLI
8 reports: 5 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "RTVue XR OCT"[tiab]. The summary above synthesizes these.
- Ganglion Cell Complex Parameters in Primary Angle Closure Suspects.
Tang Y, Pan X, Cao K, et al. · Ophthalmic Res · 2021
- Repeatability of Choroidal Thickness Measurements in Healthy Subjects using RTVue XR Optical Coherence Tomography.
Mansoori T, Charan ASR, Suresh N, et al. · J Curr Ophthalmol · 2022
- Corneal epithelial remodeling following myopic ray-tracing-guided laser-assisted in situ keratomileusis: A clinical study.
Luo L, Fan Y, Wang X, et al. · Photodiagnosis Photodyn Ther · 2025
- Valsalva Maneuver and Peripapillary OCT Angiography Vessel Density.
Holló G · J Glaucoma · 2018
- Repeatability and agreement of total corneal and sublayer pachymetry with 2 different algorithms of Fourier-domain optical coherence tomography in myopic and postphotorefractive keratectomy eyes.
Latifi G, Mohammadi SS · J Cataract Refract Surg · 2020
- Influence of Removing the Large Retinal Vessels-related Effect on Peripapillary Vessel Density Progression Analysis in Glaucoma.
Holló G · J Glaucoma · 2018
- The role of corneal epithelial thickness parameters with different degrees of keratoconus in the diagnosis of keratoconus.
Wang T, Cao Q · Mol Vis · 2026
- Influence of Posterior Subcapsular Cataract on Structural OCT and OCT Angiography Vessel Density Measurements in the Peripapillary Retina.
Holló G · J Glaucoma · 2019
Other devices of this type
Also filed under product code HLI.
- Rta Model D Retinal Thickness AnalyzerTalia Technology , Ltd. · 510(k) 2004
- Stratusoct with Rnfl & Macula Normative DatabaseCarl Zeiss Meditec, Inc. · 510(k) 2004
- EnFocus 2300, EnFocus 4400Bioptigen, Inc. · 510(k) 2015
- OCT-CameraOptomedical Technologies GmbH · 510(k) 2015
- Propper Insight Binocular Indirect OphthalmosopePropper Manufacturing Co., Inc. · 510(k) 2014
- Centervue Macular Integrity AssessmentCentervue S.P.A. · 510(k) 2014
- Amico DH-W35 Ophthalmoscope SeriesAmico Diagnostic Incorporated · 510(k) 2014
- Ivue 500Optovue, Inc. · 510(k) 2014
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.